- Home
- NCNA vs CDIO Comparison
NCNA vs CDIO Comparison
Compare NCNA & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCNA
- CDIO
- Stock Information
- Founded
- NCNA 1997
- CDIO 2017
- Country
- NCNA United Kingdom
- CDIO United States
- Employees
- NCNA N/A
- CDIO N/A
- Industry
- NCNA Biotechnology: Pharmaceutical Preparations
- CDIO Biotechnology: Commercial Physical & Biological Resarch
- Sector
- NCNA Health Care
- CDIO Health Care
- Exchange
- NCNA Nasdaq
- CDIO Nasdaq
- Market Cap
- NCNA 7.6M
- CDIO 6.4M
- IPO Year
- NCNA 2017
- CDIO N/A
- Fundamental
- Price
- NCNA $6.88
- CDIO $4.17
- Analyst Decision
- NCNA
- CDIO
- Analyst Count
- NCNA 0
- CDIO 0
- Target Price
- NCNA N/A
- CDIO N/A
- AVG Volume (30 Days)
- NCNA 768.1K
- CDIO 35.8K
- Earning Date
- NCNA 11-24-2025
- CDIO 11-12-2025
- Dividend Yield
- NCNA N/A
- CDIO N/A
- EPS Growth
- NCNA N/A
- CDIO N/A
- EPS
- NCNA N/A
- CDIO N/A
- Revenue
- NCNA N/A
- CDIO $19,507.00
- Revenue This Year
- NCNA N/A
- CDIO $1,434.82
- Revenue Next Year
- NCNA N/A
- CDIO $4,661.91
- P/E Ratio
- NCNA N/A
- CDIO N/A
- Revenue Growth
- NCNA N/A
- CDIO N/A
- 52 Week Low
- NCNA $2.78
- CDIO $3.22
- 52 Week High
- NCNA $446.00
- CDIO $53.10
- Technical
- Relative Strength Index (RSI)
- NCNA 74.46
- CDIO 53.40
- Support Level
- NCNA $3.79
- CDIO $3.81
- Resistance Level
- NCNA $5.07
- CDIO $4.63
- Average True Range (ATR)
- NCNA 0.56
- CDIO 0.32
- MACD
- NCNA 0.18
- CDIO 0.03
- Stochastic Oscillator
- NCNA 99.06
- CDIO 36.74
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
About CDIO Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.